GenScript Pro B io, a Nanjing CDMO, agreed to license a bispecific antibody to REMD Bio for an undisclosed target. REMD is a clinical stage San Francisco-Beijing biologics company.  REMD will pay GenScript ProBio service fees, commercialization milestones and royalties. The bispecific antibody is derived from single-domain antibody fused to GenScript's monoclonal antibody (SMAB) platform. In 2019, the two companies formed a collaboration to develop several novel bispecific cancer immunotherapy candidates. More details.... Share this with colleagues: // //